Document is current
Any future updates will be listed below
-
Authors
Scheres, Lotte M. J. https://orcid.org/0000-0002-0262-0540
Kujovic-Aleksov, Stefani
Winkens, Bjorn
de Crom, Ronald M. P. C.
Webers, Carroll A. B.
Beckers, Henny J. M. https://orcid.org/0000-0001-9406-1426
- License Information
-
More Information
Article History
Received: 24 May 2024
Revised: 29 January 2025
Accepted: 7 February 2025
First Online: 20 February 2025
Competing interests
: Financial Disclosures: LS, SK, and BW (none); RC: Consultant—Abbvie, Iridex, Théa Pharma; Lectures—Iridex, Santen Pharmaceutical Co. Ltd, Théa Pharma, Tramedico; CW: Consultant—Novartis, Théa Pharma; Support—Novartis, Santen Pharmaceutical Co. Ltd; HB: Consultant—InnFocus Inc. (a Santen Pharmaceutical Co. Ltd. company), Santen Pharmaceutical Co. Ltd, Glaukos, Abbvie, Novartis, Théa Pharma, Elios, Nova Eye Medical; Research support—InnFocus Inc. (a Santen Pharmaceutical Co. Ltd. company); Investment interest: Peyeoneer Medtech B.V.
